ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Taiwan says China blocked its deal with BioNTech for COVID shots

Beijing denies such action and offers to provide island itself as 'goodwill'

Taiwa wants to secure more doses of COVID-19 vaccines as infection cases surge.   © Reuters

TAIPEI (Reuters) -- Taiwan directly accused China for the first time on Wednesday of blocking a deal with Germany's BioNTech SE for COVID-19 vaccines, in an escalating war of words after Beijing offered the shots to the island via a Chinese company.

Taiwan has millions of vaccine doses on order, from AstraZeneca and Moderna, but has received only slightly more than 700,000 to date, and has only been able to vaccinate about 1% of its population as cases surge.

While Taiwan has previously said it had been unable to sign a final contract with BioNTech, it had only implied that Chinese pressure was to blame.

China claims Taiwan as its own territory and frequently puts pressure on countries and firms to curtail their dealings with the island.

In comments at a meeting of Taiwan's ruling Democratic Progressive Party, President Tsai Ing-wen said orders for the AstraZeneca and Moderna shots had been "smoothly" booked.

"As for Germany's BioNTech, we were close to completing the contract with the original German plant, but because of China's intervention, up to now there's been no way to complete it," she said.

BioNTech declined to comment on Tsai's remarks, but added "we are supportive of global vaccine supply".

China has denied trying to block vaccines for Taiwan and has offered to provide them itself to the island as a gesture of goodwill.

China's Shanghai Fosun Pharmaceutical Group Co. said on Saturday it was willing to provide Taiwan with BioNTech COVID-19 vaccines.

Fosun signed a deal with BioNTech to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan.

But Tsai said the island would only buy directly from the original manufacturers, or discus purchases with them via the COVAX global vaccine sharing scheme.

"Only by negotiating with the original manufacturer can you obtain the original manufacturer's direct guarantee and responsibility for quality and safety, so as to avoid legal and political risks," she said.

Fosun has not responded to several requests for comment.

Earlier on Wednesday, Zhu Fenglian, spokeswoman for China's Taiwan Affairs Office, said Taiwan's government was using excuses to stop vaccines from going there from China.

China was "happy to see" Fosun's willingness to provide shots to Taiwan, she added.

With supplies tight, several Taiwan politicians have said the need for the Fosun shots was so urgent the government should immediately bring them in.

But Taiwan's Health Minister Chen Shih-chung said at a daily news briefing they had seen no supporting documentation about the vaccine Fosun was offering.

"Bring out the official documents and we can talk about it again."

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more